Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain - Trial NCT06247813
Access comprehensive clinical trial information for NCT06247813 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ethos Research & Development and is currently Recruiting. The study focuses on Chronic Pain. Target enrollment is 75 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ethos Research & Development
Timeline & Enrollment
Phase 2
Feb 01, 2024
Jul 30, 2025
Primary Outcome
Quantitative urine biomarker levels.,Quality-of-life measures.,Quality-of-life measures.
Summary
The goal of this study is to use pain-specific urine biomarkers to evaluate how daily
 nutritional supplementation with biomarker guided formulas effect, quality of life and
 urinary biomarker scores in chronic pain patients. Assessing the effect of biomarker guided
 supplementation on pain specific biomarkers through changes in urinary biomarker scores may
 solidify the necessity for identifying deficiencies to create an individualized treatment
 plan for pain patients. This study aims to evaluate the effect of biomarker-guided
 supplementation on the three categories of urinary biomarkers using targeted ingredients
 specifically designed for oxidative stress, inflammation, and nerve health. This study
 provides subjects with one of three nutritional supplement formulas based on their specific
 urinary biomarker test results and assesses changes in their urinary biomarker levels and
 their quality of life as it relates to their pain over a 3-month period.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06247813
Non-Device Trial